Fig. 2From: Cardiac events during treatment with proteasome inhibitor therapy for multiple myelomaCumulative incidence of cardiac adverse events. Cumulative incidence of cardiac adverse events associated with bortezomib (solid line) and carfilzomib (dashed line) in relation to duration of therapy shown in daysBack to article page